US Stock MarketDetailed Quotes
AIMT Aimmune Therapeutics
- 0.000
- 0.0000.00%
Close Nov 22 09:30 ET
0Market Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)65.45MShares34.56052wk High0.00P/B0Float Cap34.48052wk Low--Dividend TTM43.20MShs Float42.000Historical High--Div YieldTTM0.00%Amplitude9.770Historical Low--Avg Price1Lot Size
Aimmune Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2020 | (Q1)Mar 31, 2020 | (FY)Dec 31, 2019 | (Q4)Dec 31, 2019 | (Q3)Sep 30, 2019 | (Q2)Jun 30, 2019 | (Q1)Mar 31, 2019 | (FY)Dec 31, 2018 | (Q4)Dec 31, 2018 | (Q3)Sep 30, 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -19.37%-55.11M | -56.70%-71.81M | -15.54%-195.41M | -1.97%-52.56M | -23.24%-50.85M | -26.30%-46.17M | -15.25%-45.83M | -69.80%-169.13M | -61.46%-51.55M | -69.62%-41.26M |
| Net income from continuing operations | -10.12%-69.24M | -59.27%-86.43M | -17.91%-248.5M | -17.37%-66.9M | -24.67%-64.46M | -19.65%-62.88M | -9.63%-54.27M | -60.48%-210.75M | -38.46%-57M | -62.63%-51.7M |
| Depreciation and amortization | 32.72%1.44M | 94.89%1.3M | 155.69%4.09M | 146.96%1.18M | 202.09%1.16M | 184.03%1.09M | 87.08%666K | 65.42%1.6M | 81.37%477K | 21.20%383K |
| Other non cash items | 168.93%3.21M | 578.22%7.22M | --4.63M | --1.18M | --1.19M | --1.19M | --1.07M | ---- | ---- | ---- |
| Change In working capital | -192.78%-5.79M | -711.99%-4.2M | 59.89%13.08M | 237.50%3.77M | 80.91%3.58M | -12.57%6.25M | -128.75%-517K | -39.51%8.18M | -166.95%-2.74M | -33.87%1.98M |
| -Change in receivables | --747K | ---772K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| -Change in inventory | ---5M | ---4.01M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| -Change in prepaid assets | -38.78%712K | 69.50%2.43M | 294.89%3.89M | 101.41%34K | 108.62%1.26M | 850.32%1.16M | 4,080.56%1.43M | -39.02%-2M | -301.17%-2.41M | 174.26%603K |
| -Change in payables and accrued expense | -159.47%-2.49M | -22.24%-1.97M | -18.43%8.24M | 3,728.00%3.63M | 59.37%2.03M | -39.36%4.19M | -179.82%-1.61M | -27.19%10.1M | -102.46%-100K | -63.61%1.28M |
| -Change in other current liabilities | -73.91%233K | 136.76%125K | 1,169.33%952K | 145.73%107K | 186.27%292K | 128.97%893K | -85.79%-340K | -93.10%75K | -137.56%-234K | -66.23%102K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -19.37%-55.11M | -56.70%-71.81M | -15.54%-195.41M | -1.97%-52.56M | -23.24%-50.85M | -26.30%-46.17M | -15.25%-45.83M | -69.80%-169.13M | -61.46%-51.55M | -69.62%-41.26M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -39.02%21.24M | 124.91%4.86M | 216.55%111.9M | 318.92%44.49M | 309.63%52.1M | 199.59%34.83M | -23.17%-19.53M | -325.58%-96.01M | -172.52%-20.32M | -302.94%-24.85M |
| Net PPE purchase and sale | 86.01%-488K | 76.75%-319K | 14.58%-8.05M | 14.91%-953K | -8.60%-2.23M | 9.64%-3.49M | 42.43%-1.37M | -46.61%-9.42M | 4.52%-1.12M | 14.33%-2.06M |
| Net investment purchase and sale | -43.30%21.73M | 128.55%5.18M | 238.52%119.95M | 336.65%45.44M | 338.35%54.34M | 223.15%38.32M | -34.77%-18.16M | -276.76%-86.59M | -165.77%-19.2M | -255.63%-22.8M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -39.02%21.24M | 124.91%4.86M | 216.55%111.9M | 318.92%44.49M | 309.63%52.1M | 199.59%34.83M | -23.17%-19.53M | -325.58%-96.01M | -172.52%-20.32M | -302.94%-24.85M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -29.53%2M | 633.80%285.48M | -81.32%55.88M | -89.00%11.11M | 27.33%3.03M | -34.97%2.84M | -79.68%38.9M | 4,488.37%299.16M | 2,729.71%100.96M | 64.11%2.38M |
| Net issuance payments of debt | --0 | 112.50%85M | --40M | --0 | --0 | --0 | --40M | --0 | --0 | --0 |
| Net common stock issuance | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 4,323.85%288.44M | 1,403.07%98M | --0 |
| Net preferred stock issuance | --0 | --199.91M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | -29.40%2.13M | -38.58%2M | 90.23%20.41M | 274.76%11.11M | 27.33%3.03M | -10.97%3.02M | 63.07%3.25M | --10.73M | 200.41%2.96M | 64.11%2.38M |
| Net other financing activities | 27.47%-132K | 67.17%-1.43M | ---4.53M | --0 | --0 | ---182K | ---4.35M | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -29.53%2M | 633.80%285.48M | -81.32%55.88M | -89.00%11.11M | 27.33%3.03M | -34.97%2.84M | -79.68%38.9M | 4,488.37%299.16M | 2,729.71%100.96M | 64.11%2.38M |
| Net cash flow | ||||||||||
| Beginning cash position | 268.15%298.42M | -25.70%79.88M | 46.30%107.51M | -2.01%76.84M | -48.96%72.56M | -61.28%81.06M | 46.30%107.51M | -40.74%73.49M | 6.23%78.42M | 68.33%142.16M |
| Current changes in cash | -275.17%-31.87M | 926.10%218.53M | -181.21%-27.63M | -89.56%3.04M | 106.72%4.28M | 87.35%-8.49M | -119.47%-26.45M | 167.34%34.02M | 8,809.88%29.09M | -499.60%-63.74M |
| Effect of exchange rate changes | --8K | --10K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| End cash Position | 267.34%266.56M | 268.15%298.42M | -25.70%79.88M | -25.70%79.88M | -2.01%76.84M | -48.96%72.56M | -61.28%81.06M | 46.30%107.51M | 46.30%107.51M | 6.23%78.42M |
| Free cash flow | -11.97%-55.6M | -52.82%-72.13M | -13.95%-203.46M | -1.61%-53.52M | -22.54%-53.08M | -22.87%-49.65M | -11.99%-47.2M | -68.39%-178.55M | -59.12%-52.67M | -62.08%-43.32M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data